M.A. Cobo Dols

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

Johan Vansteenkiste, Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. · Annals of Oncology · 2017 · 33 citations

Medicine, Oncology, Pharmacotherapy +15

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

Johan Vansteenkiste, Thanyanan Reungwetwattana, Ken Nakagawa et al. · Annals of Oncology · 2017 · 14 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial

Benjamin Besse, M.R. García Campelo, M.A. Cobo Dols et al. · Annals of Oncology · 2021 · 12 citations

Medicine, Oncology, Pharmacology +14